Leadership

CLINEXEL Strengthens Leadership with New Senior-Level Appointment

CLINEXEL, a full-service Clinical Research Organization (CRO) known for its high-quality, cost-effective clinical trials across Phases I to IV, has announced a significant addition to its leadership team. Dr. Mukesh Kumar, a renowned expert in clinical research and development, has been appointed as the Chief Scientific Officer (CSO).

With an impressive career spanning global pharmaceutical giants such as Sanofi and Daiichi Sankyo, as well as leading Indian companies like Cipla, Dr. Reddy’s Laboratories, and Lupin, Dr. Kumar brings a wealth of experience to CLINEXEL. His extensive expertise includes clinical trials, clinical pharmacology, translational research, biopharmaceutics, and clinical development. He has played a pivotal role in over 100 successful product registrations across regulatory landscapes, including the USFDA, EMA, India, PMDA, and ROW regions.

As CSO, Dr. Kumar will lead all clinical R&D activities and oversee clinical trial operations from Phases I to IV. His focus will be on optimizing clinical strategies, enhancing global clinical development, and driving impactful scientific negotiations for innovative therapies, biosimilars, and complex generics. His proven track record of implementing cost-effective and innovative clinical trials is expected to add substantial value to CLINEXEL’s clinical programs.

“I am excited to join the experienced and talented team at CLINEXEL. This team has a very successful track record of conducting clinical trials of all phases, for innovative products,” said Dr. Kumar.

Dr. Deepa Arora, CEO of CLINEXEL, expressed her enthusiasm, stating, “I am excited that Dr. Mukesh has decided to join the CLINEXEL team. His appointment underscores our commitment to excellence in clinical trials and clinical development programs by providing best-in-class services and strengthening our position as a trusted partner in the global clinical research landscape.”

About CLINEXEL CLINEXEL is a leading full-service clinical research organization, specializing in executing high-quality, cost-effective clinical trials across Phases I to IV. The company provides comprehensive clinical trial execution and development services for a broad range of product categories, including innovative therapies, 505(b)(2), and repurposed drugs for markets in the USA, EU, and ROW.

For more information, visit www.clinexel.com

Wem India

Share
Published by
Wem India

Recent Posts

AblyWorks’ AI Recruiter and ATS Drew Strong Enterprise Interest at TechHR India 2026

AblyWorks saw strong enterprise interest in its AI powered recruitment and hiring technology following its…

11 hours ago

AI identifies suitable herbal synergies, delivery systems, and target resonance bands: Greenspace Herbs Founder

Ayurveda has been used for thousands of years, but that history does not easily fit…

11 hours ago

Global upheavals have led to more transparent supply chains in the nutraceutical industry: Nutrify Today Founder

AI is already helping to understand individual health patterns and create more targeted nutrition solutions,…

11 hours ago

Silex World Advanced India as a Strategic Base for Critical Materials Processing

India’s growing industrial capabilities were becoming an increasingly important part of Silex World Ltd’s international…

1 day ago

Building from Akola: How Pranjali Kharche Built a Fashion Brand from a Tier-3 City

A young woman founder on choosing home, confronting the realities of regional entrepreneurship and carrying…

1 day ago

Original Design Manufacturer (ODM) opportunity in India alone is more than $100 billion: Rapidise CEO

Globally, the strongest ODM ecosystem has largely been concentrated in China, with some presence in…

2 days ago